Prism Medico and Pharmacy's upcoming Annual General Meeting includes a major strategic shift.

The company proposes to reallocate 23 Cr from a preferential issue, initially planned for a new manufacturing plant, to acquire a controlling 71.32% stake in Infuze Well Private Limited (IWPL), making it a subsidiary.

This move is aimed at faster manufacturing capacity expansion with lower execution risk.

IWPL is currently owned by the Whole-Time Director and her family, making this a material related party transaction.

Shareholders will also consider approving the annual financial results and other related party transactions up to 70 Cr for the financial year.